BioSpace News Archive

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, has filed its 2023 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2023.

TFF Pharmaceuticals, Inc announced the pricing of a public offering of an aggregate of 1,665,219 shares of its common stock and warrants to purchase up to 1,665,219 shares of common stock at a combined public offering price of $2.875 per share and accompanying warrant.

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company” or “Sona”) announces further results from the triple negative breast cancer murine model portion of its current research study at Dalhousie University (the “Study”) which confirms that the previously reported tumor volume reduction was due to activation of a tumor specific systemic immune response.

Justera Health Ltd. (CSE: VTAL) (OTC Pink: SCRSF) (“Justera” or the “Company”) today announces the resignation of Tyler Burpee from its board for personal reasons, effective April 24, 2024.

Tthe U.S. Food and Drug Administration took action aimed at helping to ensure the safety and effectiveness of laboratory developed tests, or LDTs, which are used in a growing number of health care decisions and about which concerns have been raised for many years.

Single Pass, Inc. is proud to announce that its Class II Kronos biopsy closure device has received clearance from the U.S. Food and Drug Administration (FDA).

The Dermatology Association of Radiation Therapy (DART) filed comments in opposition to a proposed change in Medicare coverage in seven states of Image-Guided Superficial Radiation Therapy (Image-Guided SRT or IGSRT) for the treatment of nonmelanoma skin cancer (NMSC).

DNB Markets (“DNB”) and Back Bay Life Science Advisors (“Back Bay”), acting through the DNB//Back Bay Healthcare Partnership are pleased to announce the dates for our highly anticipated 9th annual Nordic-American Healthcare Conference (NAHC).

FDA Quality and Regulatory Consultants (FDAQRC) begins Qualified Persons (QP) services. “We are adding this service to our product line to enhance client compliance and assist in product release efficiency for UK and EU drug releases, “said company president Chris Rush.

Kedrion Biopharma Inc. announced today that plasminogen deficiency type 1 (PLGD-1) patients in the U.S. now have access to RYPLAZIM® (plasminogen, human-tvmh).